Prompted by the observations that high intracellular expression of TRAIL-R2 correlates with poor clinical prognostic parameters [13, 14], we set out to explore the role of this particular member of the death receptor family in the malignancy of breast cancer cells, particularly in their capacity to metastasize to the bone. The gene discussed is TNFRSF10B; the disease is breast carcinoma.